Patient self-injection of methotrexate for inflammatory arthritis: A study evaluating the introduction of a new type of syringe and exploring patients' sense of empowerment

Musculoskeletal Care

Volumn 6, Issue 1, 2008, Pages 15-30

  Hiley, Jennifer ^a,c   Homer, Dawn ^a   Clifford, Collette ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Empowerment; Inflammatory arthritis; Methotrexate; Self injection

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTHRITIS; ARTICLE; BEHAVIOR; DRUG SELF ADMINISTRATION; EVALUATION; FEMALE; HUMAN; MALE; MIDDLE AGED; QUESTIONNAIRE; SYRINGE; TREATMENT OUTCOME;

ADULT; AGED; ARTHRITIS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POWER (PSYCHOLOGY); QUESTIONNAIRES; SELF ADMINISTRATION; SYRINGES; TREATMENT OUTCOME;

EID: 45149128195     PISSN: 14782189     EISSN: 15570681     Source Type: Journal    
DOI: 10.1002/msc.114     Document Type: Article

References (29)

1. Arthritis Research Campaign (ARC) (2002). Arthritis: the big picture. ARC. Available at http://www.arc.org.uk/common/contact.asp [Accessed April 15th 2005].
2. Arthur V, Jubb D, Homer D (2002). A study of parenteral use of MTX in rheumatic conditions. Journal of Clinical Nursing. 11: 256-263.
3. Arthur V (1995). Drug therapy for patients with rheumatoid arthritis. British Journal of Nursing. 5: 617-621.
4. Barlow J, Turner A, Wright C (1998). Sharing, caring and learning to take control: self-management training for people with arthritis. Psychology, Health and Medicine. 3: 387-393.
5. Bingham S, Buch M, Lindsay S, Pollard A, White J, Emery P (2003). Parenteral MTX should be given before biological therapy (Letters to the editor). Rheumatology 42: 1009-1010.
6. Brooks P, Spruill W, Parish R, Birchmore D (2003). Pharmacokinetics of MTX administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis & Rheumatism 33: 91-94.
7. Burbage G (2004). Development of self-administered cytotoxic therapy programme. NHS: The improvement network. Available at http://www.tin.nhs.uk/events-calendar/success-2004/award-winners/hidden/ cytotoxic-therapy [Accessed April 15th 2005].
8. Cradock S (2004). Helping patients to improve self management of diabetes. Heart 90: 36-38.
9. Department of Health (1998). An organisation with a memory. London, Department of Health.
10. Department of Health (2000). A fi rst class service. London, Department of Health.
11. Department of Health (2001). The expert patient: a new approach to chronic disease management for the 21st century. London, Department of Health.
12. Department of Health (2004). Improving chronic disease management. London, Department of Health.
13. Department of Health (2005). Supporting people with long term conditions: an NHS and social care model to support local innovation and integration. London, Department of Health.
14. Department of Health (2006). Our health, our care, our say: a new direction for community services. London, Department of Health.
15. Fleming G, McKenna M, Murchison V, Wood Y, Nixon J, Rogers T, Hutcheson F (2003). Using self-effi cacy as a client-centred outcome measure. Nursing Standard. 17: 33-36.
16. Gibson H (1991). A concept analysis of empowerment. Journal of Advanced Nursing 16: 354-361.
17. Health and Safety Executive (HSE) (2003). Safe handling of cytotoxic drugs. HSE information sheet MISC615. London, HSE.
18. Jobanputra P, Wilson J, Douglas K, Burls A (2004). A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology 43: 206-210.
19. Jundt J, Browne B, Fiocco G, Steele D, Mock D (1993). A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. Journal of Rheumatology 20: 1845-1849.
20. Kremer J, Phelps C (1992). Long-term prospective study of the use of MTX in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis & Rheumatism 35: 139-145.
21. Lindsay G, Russell-White C, Sandhu S, Livingstone J, Luqmani R (2000). Self-administration of sub-cutaneous MTX (SC MTX): a survey of patient benefi t and convenience. Rheumatology 39 (Suppl. 1): 88.
22. MedacUK (2005). Metoject frequently asked question sheet. Stirling, MedacUK.
23. Oppenheim A (1992). Questionnaire design, interviewing and attitude measurement. London, Pinter.
24. Ostrov B, Robbins L, Ferriss J, Newman E, Maclary S, Ayoub W, Harrington T, Perruquet J (1998). Improved tolerance and cost-effectiveness of subcutaneous versus oral MTX in rheumatoid arthritis and juvenile rheumatoid arthritis. Arthritis & Rheumatism. 41 (Suppl. S75): abstract. no. 257.
25. Polit D, Beck C, Hungler B (2001). Essentials of nursing research: Methods, appraisal, and utilization (5th edn). Philadelphia, PA, Lippincott.
26. Poulton B (1999). User involvement in identifying health needs and shaping and evaluating services: is it being realised? Journal of Advanced Nursing 30: 1289-1296.
27. Royal College of Nursing (RCN) (2004). Administering subcutaneous MTX for inflammatory arthritis: RCN guidance for nurses. London, RCN.
28. Wegrzyn J, Adeleine P, Miossec P (2004). Better effi cacy of MTX given by intramuscular injection than orally in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 63: 1232-1234.
29. Wilson J (1999). Acknowledging the expertise of patients and their organisations. British Medical Journal 319: 771-774.